Skip to content

68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors

Neuroendocrine Tumors (NET)

To determine if 68Ga-HA-DOTATATE PET/CT imaging is effective at diagnosing somatostatin positive tumors compared to conventional imaging \[including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET/CT, as available\]

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

1. Male or female. If female of child-bearing potential and outside of the window of 10 days since the last menstrual period, a negative pregnancy test will be required.
2. Age greater than or equal to 18 years.
3. Able and willing to follow instructions and comply with the protocol.
4. Provide written informed consent prior to participation in the study.
5. Clinically suspected (patients presenting with symptom(s) suggestive of carcinoid syndrome or biochemically suggestive of Neuroendocrine Tumor) or Biopsy proven Neuroendocrine Tumor

Exclusion Criteria:

1. Nursing or pregnant females.
2. Age less than 18 years.
3. Surgery in the area of interest within the preceding 2 months.

Study Location

Foothills Medical Center 1403 29 St NW
Foothills Medical Center 1403 29 St NW
Calgary, Alberta
Canada

Contact Study Team

Backup Contact

Kirstie Lithgow, MD

[email protected]
403-388-6301
Primary Contact

Denise Chan, MD

[email protected]
4039441252
Study Sponsored By
Alberta Health services
Participants Required
More Information
Study ID: NCT05673031